Genomics, Proteomics, and the Nervous System | E-Book | www.sack.de
E-Book

E-Book, Englisch, 592 Seiten

Genomics, Proteomics, and the Nervous System


1. Auflage 2010
ISBN: 978-1-4419-7197-5
Verlag: Springer-Verlag
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 592 Seiten

ISBN: 978-1-4419-7197-5
Verlag: Springer-Verlag
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)



This newest volume of Advances in Neurobiology discusses the utilization of genomic and proteomic technologies, to address facets of neurobiology including development and epigenetic regulation, functions in learning and memory, and changes associated with neurological and psychiatric disorders.

Genomics, Proteomics, and the Nervous System jetzt bestellen!

Autoren/Hrsg.


Weitere Infos & Material


1;Genomics, Proteomics,and the Nervous System;3
1.1;Preface;5
1.2;Contents;7
1.3;Contributors;11
1.4;Part I:Development;17
1.4.1;The Genomics of Turner Syndrome and Sex-Biased Neuropsychiatric Disorders;18
1.4.1.1;1 Turner Syndrome;18
1.4.1.1.1;1.1 Genetic Mechanisms Underlying TS Endophenotypes;20
1.4.1.1.2;1.2 Problems with Investigating the Genomics of TS;21
1.4.1.1.3;1.3 Identification of Candidate Genes for TS Endophenotypes;22
1.4.1.1.3.1;1.3.1 Human Studies;22
1.4.1.1.3.2;1.3.2 Mouse Studies;24
1.4.1.2;2 The Genomics of Sex-Biased Neuropsychiatric Disorders;26
1.4.1.3;3 Insights into Sex-Biased Neuropsychiatric Disorders from Turner Syndrome;28
1.4.1.4;4 Conclusion;29
1.4.1.5;References;30
1.4.2;Mental Retardation and Human Chromosome 21 Gene Overdosage: From Functional Genomics and Molecular Mechanisms Towards Prevention and Treatment of the Neuropathogenesis of Down Syndrome;36
1.4.2.1;1 Mental Retardation in Down Syndrome: An Invalidating Neuropathological Aspect with Hard Impact on Public Health;38
1.4.2.2;2 Mental Retardation in Down Syndrome: A Consequence of Developmental and Functional Brain Alterations;39
1.4.2.3;3 Mental Retardation in Down Syndrome: A Consequence of Chromosome 21 Gene Overdosage;41
1.4.2.3.1;3.1 Chromosomal Imbalance Effects on Mental Retardation;41
1.4.2.3.1.1;3.1.1 Dosage-Sensitive Gene Hypothesis;42
1.4.2.3.1.2;3.1.2 Amplified Developmental Instability Hypothesis;43
1.4.2.3.2;3.2 Gene Dosage Imbalance in Down Syndrome Determine Dysregulation of HSA21 Gene Expression;43
1.4.2.3.2.1;3.2.1 Primary and Secondary Gene Effects;43
1.4.2.3.2.2;3.2.2 Transcriptional Variation as a Consequence of Trisomy 21;44
1.4.2.3.2.3;3.2.3 Proteomic Variation as a Consequence of Trisomy 21;48
1.4.2.4;4 Modelling Neuronal Alterations and Mental Retardation in Mouse Models of Down Syndrome;51
1.4.2.4.1;4.1 Trisomic Mouse Models and Candidate Chromosomal Regions for Mental Retardation in Down Syndrome;52
1.4.2.4.1.1;4.1.1 Ts16 Mice: Trisomic for Most Part of HSA21 with Three Copies of Complete MMU16;53
1.4.2.4.1.2;4.1.2 Segmental Ts65Dn Mice: Trisomic for Most HSA21 Genes Conserved in Distal End of MMU16;53
1.4.2.4.1.3;4.1.3 Segmental Ts1Cje Mice: Trisomic for Three-Quarters of Genes of Ts65Dn, Including DSCR;55
1.4.2.4.1.4;4.1.4 Segmental Ms1Ts65 Mice: Trisomic for Non-DSCR Genes of Ts65Dn and Missing from Ts1Cje;55
1.4.2.4.1.5;4.1.5 Segmental Ts1Rhr and Ms1Rhr Mice: Trisomic and Monosomic for DSCR;56
1.4.2.4.1.6;4.1.6 Segmental Ts2Cje Mice: Trisomic from APP to the Telomere;56
1.4.2.4.1.7;4.1.7 Segmental Dp(16)1Yu Mice: Trisomic from LIP1 to ZNF295;57
1.4.2.4.1.8;4.1.8 Transchromosomal ES(#21) Mice: Trisomic for a Large Part of HSA21;57
1.4.2.4.1.9;4.1.9 Transchromosomal TC1 Mice: Trisomic for Almost HSA21 (92% of HSA21 Genes);58
1.4.2.4.1.10;4.1.10 Segmental Transgenic Mouse In Vivo Library of Human DSCR;58
1.4.2.5;5 Genetic Dissection of the Role of the Down Syndrome Critical Region in Mental Retardation;59
1.4.2.6;6 Transgenic Mouse Models of Down Syndrome;60
1.4.2.7;7 Candidate Genes and Genotype/Phenotype Correlation for Mental Retardation in Down Syndrome;61
1.4.2.7.1;7.1 Cu-Zn Superoxide Dismutase (SOD1) Gene;61
1.4.2.7.2;7.2 Amyloid Precursor Protein (APP) Gene;63
1.4.2.7.3;7.3 v-ets Erythroblastosis Virus E26 (ETS2) Gene;64
1.4.2.7.4;7.4 S100 Calcium Binding Protein B (S100B) Gene;64
1.4.2.7.5;7.5 Dual-Specificity Tyrosine Y Kinase 1 Subunit A (DYRK1A) Gene;65
1.4.2.7.6;7.6 Single-Minded (SIM2) Gene;66
1.4.2.7.7;7.7 Regulator of the Calcineurin (RCAN1) Gene;67
1.4.2.7.8;7.8 DOPEY2 Gene;68
1.4.2.7.9;7.9 Potassium Inwardly Rectifying Channel (KCNJ6) Gene;69
1.4.2.7.10;7.10 Tetratricopeptide Down Syndrome (TPRD) Gene;70
1.4.2.7.11;7.11 Down Syndrome Cell Adhesion Molecule (DSCAM) Gene;71
1.4.2.7.12;7.12 Synaptoganin 1 (SYNJ1) Gene;71
1.4.2.7.13;7.13 Intersectin 1 (ITSN1) Gene;72
1.4.2.7.14;7.14 Contribution of MicroRNAs in Down Syndrome Mental Retardation;73
1.4.2.8;8 Potential Molecular Pathways and Mechanisms Involved in Mental Retardation of Down Syndrome;74
1.4.2.8.1;8.1 Molecular and Cellular Mechanisms Leading to Mental Retardation in Down Syndrome;74
1.4.2.8.2;8.2 Molecular Pathways Contributing to Mental Retardation in Down Syndrome;76
1.4.2.9;9 Potential Directions for Mental Retardation Therapeutics in Down Syndrome;79
1.4.2.10;10 Conclusion and Perspectives;81
1.4.2.11;References;82
1.4.3;Epigenetic Programming of Stress Responses and Trans-Generational Inheritance Through Natural Variations in Maternal Care;102
1.4.3.1;1 Introduction: Environmental Influences and the Origins of Adult Health and Disease;103
1.4.3.2;2 Maternal Care in the Rat and HPA and Behavioral Responses to Stress in Adulthood;104
1.4.3.3;3 Epigenetic Gene Regulation: Heritable Changes in Gene Expression Potential;106
1.4.3.3.1;3.1 Chromatin Structure;106
1.4.3.3.2;3.2 DNA Methylation;107
1.4.3.3.3;3.3 DNA Demethylation;108
1.4.3.4;4 DNA Methylation and the Maternal Programming of Stress Responses;109
1.4.3.4.1;4.1 Epigenetic Programming by Maternal Care Is Reversible in the Adult Animal;110
1.4.3.4.2;4.2 Mechanisms Leading from Maternal Care to Chromatin Plasticity;112
1.4.3.5;5 Trans-Generational Inheritance of Epigenetic Programming by Maternal Behavior;113
1.4.3.5.1;5.1 Evidence for Epigenetic Mechanisms Linking Maternal Care of the Mother with Maternal Behavior in the Female Offspring;114
1.4.3.5.2;5.2 Environmental Influences and the Mother–Offspring Dyad;115
1.4.3.6;6 Epigenetic Programming Early in Life and Inter-Individual Differences in Human Behavior and Health;117
1.4.3.7;7 Concluding Remarks;118
1.4.3.8;References;119
1.4.4;Prenatal Viral Infection in Mouse: An Animal Model of Schizophrenia;128
1.4.4.1;1 An Introduction to Prenatal Viral Infectionand Schizophrenia;128
1.4.4.2;2 Mouse Brain Development;130
1.4.4.3;3 Impact of Prenatal Viral Infection on Brain Development;131
1.4.4.3.1;3.1 Brain Structural Abnormalities Following PrenatalViral Infection;131
1.4.4.3.2;3.2 Brain Gene Expression Abnormalities FollowingPrenatal Viral Infection;133
1.4.4.3.3;3.3 Altered Protein Expression in Offspring Following Prenatal Viral Infection;136
1.4.4.3.4;3.4 Brain Neurotransmitters are Altered in Exposed Offspring Following Viral Infection at E16 and E18;142
1.4.4.3.5;3.5 Abnormal Behavior of Offspring Following PrenatalViral Infection;143
1.4.4.4;4 Conclusions;143
1.4.4.5;References;146
1.4.5;Proteomic Actions of Growth Hormone in the Nervous System;152
1.4.5.1;1 Introduction;153
1.4.5.2;2 GH and Neural Action;154
1.4.5.3;3 GH and Neural Protein Synthesis;157
1.4.5.4;4 GH and Neural Growth and Differentiation;158
1.4.5.5;5 GH and Neuroprotection;161
1.4.5.6;6 GH and Neurotransmission;163
1.4.5.7;7 GH and Neuroendocrine Function;163
1.4.5.8;8 GH and Behavior;164
1.4.5.8.1;8.1 Summary;164
1.4.5.9;References;165
1.5;Part II:Learning and Memory;174
1.5.1;Gene Expression and Signal Transduction Cascades Mediating Estrogen Effectson Memory;175
1.5.1.1;1 Introduction;175
1.5.1.2;2 Synaptic Plasticity: A Memory Model;176
1.5.1.2.1;2.1 Long-Term Potentiation;177
1.5.1.3;3 Genomic Processes;178
1.5.1.3.1;3.1 Estrogen Receptors;178
1.5.1.3.1.1;3.1.1 Estrogen Receptor Localization;178
1.5.1.4;4 Rapid Signaling Cascades;179
1.5.1.4.1;4.1 Calcium Regulation;179
1.5.1.4.2;4.2 Alteration in Kinase and Phosphatase Activity;180
1.5.1.5;5 Interaction of Rapid Signaling Cascades and Transcription;180
1.5.1.5.1;5.1 Trophic and Neuroprotective Influences;182
1.5.1.5.2;5.2 Age-Related Changes in Estrogen Pathways;183
1.5.1.6;6 Conclusion;183
1.5.1.7;References;184
1.5.2;Diagnostic Genome Profiling in Mental Retardation;191
1.5.2.1;1 Introduction;191
1.5.2.2;2 Conventional Cytogenetics;193
1.5.2.3;3 Molecular Cytogenetics;193
1.5.2.3.1;3.1 Fluorescence In Situ Hybridization;193
1.5.2.3.2;3.2 Molecular Karyotyping;194
1.5.2.3.2.1;3.2.1 Clone-Based Genomic Microarrays;195
1.5.2.3.2.2;3.2.2 High-Density Oligonucleotide Microarrays;195
1.5.2.4;4 High Throughput Screening Technologies in Mental Retardation;197
1.5.2.4.1;4.1 Identification of Genes in Known Mental Retardation Syndromes;197
1.5.2.4.2;4.2 Targeted Microarray Applications;198
1.5.2.4.3;4.3 Genome-Wide Screening for DNA Copy-Number Variation;198
1.5.2.4.3.1;4.3.1 Identification of New Genomic Disorders;199
1.5.2.5;5 Copy-Number Variants in the General Population;200
1.5.2.6;6 The Clinical Consequences of Submicroscopic Copy-Number Variants;201
1.5.2.7;7 Conclusions and Future Prospects;203
1.5.2.8;References;203
1.5.3;Genomic Imprinting and Sexual Experience-Dependent Learning in the Mouse;209
1.5.3.1;1 Introduction;210
1.5.3.1.1;1.1 Olfaction and Male Reproduction;210
1.5.3.1.2;1.2 Genomic Imprinting and Reproduction;211
1.5.3.2;2 The Effects of Sexual Experience on Male Behaviour;212
1.5.3.2.1;2.1 Behavioural Responses to Sexual Experience;212
1.5.3.2.1.1;2.1.1 Sexual Experience and Reproductive Behaviours;212
1.5.3.2.1.2;2.1.2 Sexual Experience and Non-Reproductive Behaviours;213
1.5.3.2.2;2.2 Male Olfactory Learning and Sexual Experience;214
1.5.3.2.2.1;2.2.1 Sexual Experience and the Accessory Olfactory System;215
1.5.3.2.2.2;2.2.2 The Main Olfactory System and Male Reproductive Behaviour;216
1.5.3.2.2.3;2.2.3 Sexual Experience and the Main Olfactory System;217
1.5.3.2.3;2.3 Neuroendocrine Responses to Sexual Experience in the Male Brain;218
1.5.3.2.3.1;2.3.1 Sexual Experience and Androgens;218
1.5.3.2.3.2;2.3.2 Sexual Experience and Dopamine;219
1.5.3.2.3.3;2.3.3 Sexual Experience and Nitric Oxide;220
1.5.3.3;3 Genomic Imprinting;221
1.5.3.3.1;3.1 Imprinted Genes in the Brain;222
1.5.3.3.1.1;3.1.1 Imprinted Genes and Brain Development;222
1.5.3.3.1.2;3.1.2 Imprinted Genes and Brain Dysfunction;223
1.5.3.3.2;3.2 Evolution of Genomic Imprinting;224
1.5.3.3.2.1;3.2.1 Genomic Imprinting in Mammals;224
1.5.3.3.2.2;3.2.2 Hypotheses for the Evolution of Genomic Imprinting;225
1.5.3.3.2.3;3.2.3 Co-adaptation and Genomic Imprinting;225
1.5.3.4;4 Paternally Expressed Gene 3 (Peg3);226
1.5.3.4.1;4.1 Peg3, Maternal Behaviour and Offspring Development;226
1.5.3.4.1.1;4.1.1 Maternal Behaviour in Peg3 Mutant Mice;226
1.5.3.4.1.2;4.1.2 Reciprocal Effects in Peg3 Mutant Mothers and Offspring;227
1.5.3.4.2;4.2 Peg3 and Male Behaviour;227
1.5.3.4.2.1;4.2.1 Peg3 and Sexual Experience-Dependent Behavioural Changes;228
1.5.3.4.3;4.3 Peg3 and Forebrain Plasticity in Response to Sexual Experience;229
1.5.3.4.3.1;4.3.1 Peg3 and the Olfactory Systems;229
1.5.3.4.3.2;4.3.2 Peg3 and the Basal Forebrain;230
1.5.3.4.3.3;4.3.3 Peg3 and Hypothalamic Oxytocin;231
1.5.3.4.3.4;4.3.4 Peg3, Brain Development and Plasticiy;232
1.5.3.5;5 Conclusion;232
1.5.3.6;References;233
1.5.4;Proteomic Analysis of the Postsynaptic Density;240
1.5.4.1;1 Introduction;240
1.5.4.2;2 Composition of the PSD;242
1.5.4.2.1;2.1 Isolation of PSDs;242
1.5.4.2.2;2.2 Identification of Proteins in PSD Fractions;242
1.5.4.2.3;2.3 Problem of Contaminants;245
1.5.4.2.4;2.4 PSD Fractions of Higher Purity;246
1.5.4.2.4.1;2.4.1 N-Lauroyl-Sarcosinate-Derived PSD Fraction;247
1.5.4.2.4.2;2.4.2 Affinity Purification of PSD Fraction Using Magnetic Beads;247
1.5.4.2.5;2.5 Validation of PSD Constituents by Biochemical Techniques;249
1.5.4.2.6;2.6 Validation of PSD Constituents by Immuno-Electron Microscopy;251
1.5.4.2.7;2.7 Quantification;252
1.5.4.2.7.1;2.7.1 Absolute Quantification;252
1.5.4.2.7.2;2.7.2 Relative Quantification;253
1.5.4.3;3 Catching the Dynamics of the PSD;254
1.5.4.3.1;3.1 Studies Monitoring Changes in the PSD Composition;254
1.5.4.3.2;3.2 Problem of Postmortem Modifications When Using Whole Animals;255
1.5.4.3.3;3.3 Another Experimental Model: PSD fraction from Hippocampal Slices;255
1.5.4.4;4 Conclusions and Perspective;258
1.5.4.5;References;259
1.6;Part III:Behavior;263
1.6.1;Functional Genomic Dissection of Speechand Language Disorders;264
1.6.1.1;1 Human Speech and Language;265
1.6.1.2;2 Disorders of Speech and Language;265
1.6.1.2.1;2.1 Developmental Verbal Dyspraxia and the KE Family;266
1.6.1.2.2;2.2 Identifying a Gene Underlying Verbal Dyspraxia;267
1.6.1.3;3 FOX Transcription Factors;268
1.6.1.4;4 Functional Properties of FOXP2;270
1.6.1.4.1;4.1 Alternative Splicing of FOXP2;270
1.6.1.4.2;4.2 Functional Consequences of FOXP2 Mutations;273
1.6.1.4.3;4.3 R553H Affects Multiple Aspects of FOXP2 Function;274
1.6.1.4.4;4.4 R328X Yields an Unstable Non-Functional Product;275
1.6.1.5;5 Regulatory Networks Associated with Human Speech and Language;276
1.6.1.5.1;5.1 High Throughput Analysis of FOXP2 Target Genes;276
1.6.1.5.2;5.2 Unbiased Identification of FOXP2 Binding;279
1.6.1.5.3;5.3 CNTNAP2 is a Direct Target of FOXP2;281
1.6.1.5.4;5.4 FOXP2 and Common Forms of Language Disorder;283
1.6.1.6;6 Conclusions/Future Perspectives;284
1.6.1.7;References;284
1.6.2;Studying Human Circadian Behaviour Using Peripheral Cells;290
1.6.2.1;1 Introduction;290
1.6.2.1.1;1.1 Basic Mechanisms of the Circadian Clock;291
1.6.2.1.2;1.2 Central and Peripheral Oscillators;292
1.6.2.1.3;1.3 Communication Between the SCN and Periphery;294
1.6.2.1.4;1.4 Mutations in Clock Genes Affect Human Circadian Behaviour;295
1.6.2.1.5;1.5 Interaction Between the Circadian Clock and Mood Disorders;295
1.6.2.2;2 Measurement of Human Circadian Clocks;296
1.6.2.2.1;2.1 Reporter Assays in Peripheral Cells;297
1.6.2.2.2;2.2 Cell Type Considerations;297
1.6.2.3;3 Protocols;300
1.6.2.3.1;3.1 Overview of Requirements;300
1.6.2.3.1.1;3.1.1 Ethical Considerations;300
1.6.2.3.1.2;3.1.2 Use of Viruses;300
1.6.2.3.1.3;3.1.3 Storage of Samples;300
1.6.2.3.2;3.2 Producing the Reporter Virus;300
1.6.2.3.2.1;3.2.1 Calcium Phosphate Transfection in 293T Cells;301
1.6.2.3.2.2;3.2.2 Optimising Virus Production;302
1.6.2.3.3;3.3 Processing of Skin Biopsies;302
1.6.2.3.3.1;3.3.1 Preparation of the Skin;302
1.6.2.3.3.2;3.3.2 Punch;303
1.6.2.3.3.3;3.3.3 Biopsy Processing;303
1.6.2.3.3.4;3.3.4 Splitting Procedure;304
1.6.2.3.3.5;3.3.5 Freezing Procedure;304
1.6.2.3.3.6;3.3.6 Thawing Process;304
1.6.2.3.4;3.4 Measurement of Circadian Oscillations from Skin Biopsies;304
1.6.2.3.4.1;3.4.1 Fibroblast Infection;304
1.6.2.3.4.2;3.4.2 Measurement of Circadian Period Length;305
1.6.2.3.4.3;3.4.3 Phase Response Experiments;305
1.6.2.3.4.4;3.4.4 Phase Entrainment Experiments;305
1.6.2.3.4.5;3.4.5 Data Analyses;306
1.6.2.3.5;3.5 Troubleshooting;306
1.6.2.4;4 Discussion;307
1.6.2.4.1;4.1 Relationship Between the Circadian Oscillator and Other Pathologies;308
1.6.2.4.2;4.2 Ex Vivo Models;308
1.6.2.4.3;4.3 Future Potential;308
1.6.2.5;References;309
1.6.3;Genome-Wide Expression Profilesof Amygdala and Hippocampus in MiceAfter Fear Conditioning;314
1.6.3.1;1 Introduction;315
1.6.3.2;2 Fear Conditioning;316
1.6.3.2.1;2.1 Fear Conditioning and Amygdala;317
1.6.3.2.2;2.2 Fear Conditioning and Hippocampus;317
1.6.3.3;3 DNA Microarrays;318
1.6.3.4;4 Gene Expression Profiling in Amygdala and Hippocampus After Fear Conditioning;319
1.6.3.4.1;4.1 Methodologies;319
1.6.3.4.1.1;4.1.1 Animals and Fear Conditioning Training;319
1.6.3.4.1.2;4.1.2 Tissue Collection and RNA Extraction;320
1.6.3.4.1.3;4.1.3 Gene Expression Analysis;321
1.6.3.4.1.4;4.1.4 Real-Time RT-PCR and Immunohistochemistry;321
1.6.3.4.2;4.2 Distinct Gene Expression Patterns Induced by Fear Conditioning in Amygdala and Hippocampus;322
1.6.3.4.2.1;4.2.1 Fear Conditioning-Triggered Gene Expression Profiles in the Amygdala;332
1.6.3.4.2.2;4.2.2 Fear Conditioning-Triggered Gene Expression Profilesin the Hippocampus;334
1.6.3.5;5 Summary;335
1.6.3.6;References;336
1.7;Part IV:Psychiatric Disorders;341
1.7.1;Genetic Studies of Schizophrenia;342
1.7.1.1;1 Introduction;342
1.7.1.2;2 Genetic Epidemiology: Why Are We Looking for Genes Contributing to Schizophrenia?;344
1.7.1.2.1;2.1 Family Studies: Does Risk Aggregate in Relatives?;345
1.7.1.2.2;2.2 Twin Studies: How Large Is the Genetic Component of Risk?;346
1.7.1.2.3;2.3 Adoption Studies: Is Familial Aggregation Due to Shared Environment?;347
1.7.1.2.4;2.4 Transmission Models: How Is the Genetic Risk Transmitted?;348
1.7.1.2.5;2.5 Spectrum Disorders: How Broad Is the Range of Psychiatric Illness Transmitted and Who Do We Consider Affected?;350
1.7.1.3;3 Methods: Where and How Will Such Genes Be Found?;352
1.7.1.3.1;3.1 Approaches: What Are Linkage and Association?;352
1.7.1.3.2;3.2 Linkage;352
1.7.1.3.3;3.3 Linkage Analysis Methods;354
1.7.1.3.4;3.4 Association;355
1.7.1.3.5;3.5 Association Analysis Methods;355
1.7.1.3.6;3.6 Limitations of Linkage and Association;356
1.7.1.3.7;3.7 DNA Polymorphisms;357
1.7.1.4;4 Results: Where Is the Evidence Strongest for Schizophrenia Susceptibility Genes?;358
1.7.1.4.1;4.1 Chromosome 22q Linkage Studies;358
1.7.1.4.2;4.2 Chromosome 22q Candidate Genes;359
1.7.1.4.2.1;4.2.1 COMT;359
1.7.1.4.3;4.3 Chromosome 8p22-p21 Linkage Studies;360
1.7.1.4.4;4.4 Chromosome 8p22-p21 Candidate Genes;360
1.7.1.4.4.1;4.4.1 NRG1;360
1.7.1.4.4.2;4.4.2 NRG1 and ERBB4;361
1.7.1.4.5;4.5 Chromosome 6p24-p22 Linkage Studies;361
1.7.1.4.6;4.6 Chromosome 6p24-p22 Candidate Genes;361
1.7.1.4.6.1;4.6.1 DTNBP1;361
1.7.1.4.6.2;4.6.2 Chromosome 13q14-q32 Linkage Studies;365
1.7.1.4.7;4.7 Chromosome 13q14-q32 Candidate Genes;365
1.7.1.4.7.1;4.7.1 G72/DAOA;365
1.7.1.4.7.2;4.7.2 G72/DAOA and DAO;366
1.7.1.4.8;4.8 Chromosome 1q32-q42 Linkage Studies;366
1.7.1.4.8.1;4.8.1 1q41-q42 and DISC1;366
1.7.1.4.9;4.9 1q23-q32 linkage and RGS4;367
1.7.1.4.10;4.10 Other Chromosomal Regions and Genes;368
1.7.1.4.11;4.11 Meta-Analyses of Linkage and Association Data;368
1.7.1.4.12;4.12 Summary of Current Gene Findings;369
1.7.1.4.13;4.13 Genomewide Association Studies;370
1.7.1.4.14;4.14 Rare Structural Variation in Schizophrenia;371
1.7.1.5;5 Discussion;373
1.7.1.6;6 Conclusions;374
1.7.1.7;References;375
1.7.2;Proteomics of the Anterior Cingulate Cortex in Schizophrenia;390
1.7.2.1;1 Introduction;391
1.7.2.2;2 Cross-Correlation of Altered Proteins in Different Brain Region, Disease and Risperidone-Treated Rats;392
1.7.2.2.1;2.1 Human ACC Samples of Schizophrenia Subjects and 2DE-Based Proteomic Analysis;392
1.7.2.2.2;2.2 Changes in the ACC GM and WM Proteomes in Schizophrenia Relative to Healthy Controls;393
1.7.2.2.3;2.3 Cross-Correlation of Identified Proteins in the ACC WM and GM Proteome in Schizophrenia;394
1.7.2.2.4;2.4 Cross-Correlation of Altered Proteins in the ACC in Schizophrenia and Prefrontal Cortex Brodmann Area 9 (PFC BA9) inAlcoholism ;396
1.7.2.2.5;2.5 Altered Proteins of the Schizophrenia ACC vs. Altered Proteins Due to Neuroleptics in Animal Brain;397
1.7.2.3;3 Schizophrenia ACC-Specific Protein Changes;398
1.7.2.4;4 Conclusions;405
1.7.2.5;References;405
1.7.3;Proteome Effects of Antidepressant Medications;408
1.7.3.1;1 Introduction;409
1.7.3.2;2 Antidepressant Treatments;410
1.7.3.2.1;2.1 Pharmacotherapy;410
1.7.3.2.2;2.2 Other Antidepressant Treatments;410
1.7.3.3;3 Proteomic Approaches for Aiding the Discovery of Novel Antidepressants;412
1.7.3.4;4 Proteomic Analyses After Antidepressant Treatments;413
1.7.3.4.1;4.1 Antidepressive Agents;413
1.7.3.4.1.1;4.1.1 Proteomics in the Early Days;413
1.7.3.4.1.2;4.1.2 Proteomics in the New Millennium;430
1.7.3.4.1.3;4.1.3 Proteomic Investigations in Cellular Models;435
1.7.3.4.2;4.2 Non-Pharmacologic Interventions;435
1.7.3.5;5 Critical Evaluations of Proteomic Techniques in Studies with Antidepressants;436
1.7.3.5.1;5.1 2D Gel Electrophoresis;436
1.7.3.5.2;5.2 Gel Matching and Differential Analysis;437
1.7.3.5.3;5.3 Protein Identification;438
1.7.3.5.4;5.4 Result Confirmation;439
1.7.3.6;6 Ongoing Studies;439
1.7.3.7;7 An Integrative Overview of Proteomic Findings;441
1.7.3.8;References;446
1.8;Part V:Neurological Disorders;451
1.8.1;MicroRNAs in Neurodegenerative Disorders;452
1.8.1.1;1 Introduction;452
1.8.1.2;2 MicroRNAs (miRNAs): A Widespread Class of Small RNA Molecules that Regulate Protein Expression;453
1.8.1.2.1;2.1 Overview of the Mammalian miRNA Expression Pathway (see Fig. 1 and review in Winter, Jung, Keller, Gregory, & Diederichs (2009);453
1.8.1.2.2;2.2 Mechanisms of miRNA Posttranscriptional Regulation;454
1.8.1.3;3 Regulatory Roles of miRNAs in Synapse Formation;455
1.8.1.4;4 A Role for miRNA Dysregulation in Neurodegenerative Disorders;456
1.8.1.4.1;4.1 Neurodegeneration as a Consequence of Deficits in miRNA Processing;456
1.8.1.4.2;4.2 miRNA Dysregulation in Human Neurodegenerative Disorders;457
1.8.1.4.3;4.3 Loss of miRNA Target Gene Binding Is Associated with Neurodegeneration;458
1.8.1.5;5 Conclusions and Future Perspectives;458
1.8.1.6;References;459
1.8.2;Specific and Surrogate Cerebrospinal Fluid Markers in Creutzfeldt–Jakob Disease;462
1.8.2.1;1 Introduction;463
1.8.2.2;2 Search for Pathological Values in Cerebrospinal Fluid of sCJD Patients;463
1.8.2.2.1;2.1 The Search for PrPSc;464
1.8.2.2.2;2.2 Search for Surrogate Markers;465
1.8.2.2.3;2.3 2D-PAGE Approach;466
1.8.2.3;3 Future Perspectives;468
1.8.2.4;References;470
1.8.3;Genome-Wide Expression Studies in Autism-Spectrum Disorders: Moving from Neurodevelopment to Neuroimmunology;475
1.8.3.1;1 Introduction;476
1.8.3.2;2 Genome-Wide Expression Studies in Autism Spectrum Disorders;477
1.8.3.3;3 Abnormal Immunity and Neuroinflammation in Autism;485
1.8.3.4;4 Conclusions and Future Perspectives;488
1.8.3.5;References;489
1.8.4;Protein Expression Profile of Alzheimer’s Disease Mouse Model Generated by Difference Gel Electrophoresis (DIGE) Approach;494
1.8.4.1;1 Introduction;495
1.8.4.2;2 Transgenic Mouse Model as a Tool for Studyof Alzheimer’s Disease Proteome;496
1.8.4.3;3 Generation of AD Proteomic Profile by DIGE Analysis;497
1.8.4.3.1;3.1 Sample Preparation and Labeling;498
1.8.4.3.2;3.2 Protein Separation and Determination of Differentiating Spots;498
1.8.4.3.3;3.3 MS Identification of Regulated Proteins;501
1.8.4.3.4;3.4 Analysis of Resulting Protein Set;503
1.8.4.4;4 Resulting Protein Expression Profile in Relation to the Current Knowledge of Alzheimer Disease;506
1.8.4.5;5 Conclusion and Perspectives;510
1.8.4.6;References;511
1.8.5;Proteomic Analysis of CNS Injury and Recovery;516
1.8.5.1;1 Introduction;517
1.8.5.2;2 Proteomics of Injury-Associated Proteins in the Mammalian CNS;517
1.8.5.2.1;2.1 Traumatic Brain Injury;517
1.8.5.2.1.1;2.1.1 Traumatic Brain Injury During Early Postnatal Development;517
1.8.5.2.1.2;2.1.2 Traumatic Brain Injury During Adulthood;519
1.8.5.2.2;2.2 Spinal Cord Injury;521
1.8.5.3;3 Proteome Analysis of Injury-Related Plasticity of the Mammalian Brain;522
1.8.5.3.1;3.1 Vestibular Compensation: The Restoration of Vestibular Function After Injury;522
1.8.5.3.2;3.2 Differential Proteome Analysis of Proteins Involved in Vestibular Compensation;523
1.8.5.4;4 Biomarkers of CNS Injury;524
1.8.5.4.1;4.1 Criteria for Useful Biomarkers;524
1.8.5.4.2;4.2 Production, Composition, and Function of the Cerebrospinal Fluid;524
1.8.5.4.3;4.3 Toward a Molecular Identification of Biomarkers of CNS Injury in Humans;525
1.8.5.5;5 Comparative Proteomic Analysis of Regeneration-Competent vs. Regeneration-Deficient Systems;526
1.8.5.5.1;5.1 Comparative Proteomics as a Strategy to Identify Novel Signals Associated with Regeneration;526
1.8.5.5.2;5.2 Regenerative Potential in the Teleost Fish Brain;527
1.8.5.5.3;5.3 Proteome Analysis of Proteins Involved in Repair of the Teleostean Brain;528
1.8.5.6;6 Potential Problems and Limitations of Proteome Analysis of Brain Injury-Associated Proteins;533
1.8.5.7;7 Perspectives;535
1.8.5.8;References;536
1.8.6;MALDI Imaging of Formalin-Fixed Paraffin-Embedded Tissues: Application to Model Animals of Parkinson Diseasefor Biomarker Hunting;542
1.8.6.1;1 What is MALDI Imaging Mass Spectrometry Procedure?;542
1.8.6.2;2 Application of MALDI-MSI to Brain Analyses;545
1.8.6.3;3 How to Apply MALDI-MSI to Archived Tissue in FFPE;546
1.8.6.4;4 Application of MALDI-MSI to Neurodegenerative Diseases: Parkinson’s Disease;547
1.8.6.5;References;556
1.8.7;Comparative Proteomic Analysis as a Method to Investigate Inflammatory and Neuropathic Pain;562
1.8.7.1;1 Introduction;563
1.8.7.2;2 Nociceptive Pain;563
1.8.7.2.1;2.1 Animal Models of Nociceptive Pain;564
1.8.7.2.1.1;2.1.1 Zymosan-Induced Paw Inflammation;564
1.8.7.3;3 Neuropathic Pain;564
1.8.7.3.1;3.1 Animal Models of Neuropathic Pain;565
1.8.7.3.1.1;3.1.1 Central Models;565
1.8.7.3.1.1.1;Weight Drop Model;565
1.8.7.3.1.1.2;Spinal Cord Hemisection;566
1.8.7.3.1.2;3.1.2 Peripheral Models;566
1.8.7.3.1.2.1;Spinal Nerve Ligation;567
1.8.7.3.1.2.2;Partial Nerve Ligation;567
1.8.7.3.1.2.3;Chronic Constriction Injury of the Sciatic Nerve;567
1.8.7.4;4 Proteomics;567
1.8.7.4.1;4.1 2D PAGE;568
1.8.7.4.2;4.2 Identification of 2D-Separated Proteins;569
1.8.7.5;5 Protein Expression Following Peripheral Inflammation;569
1.8.7.6;6 Protein Expression Following Neuropathic Pain;570
1.8.7.7;7 Conclusion;572
1.8.7.8;References;583
1.9;Index;588



Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.